+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Discovery Services and Platforms Market: Distribution by Type of Service Offered, Antibody Discovery Method, Nature of Antibody Generated and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 536 Pages
  • March 2022
  • Region: Global
  • Roots Analysis
  • ID: 5557818
Description Jump to:
Since the approval of Orthoclone OKT3, a murine monoclonal antibody against T cell expressed CD3 (for the treatment of acute transplant rejection) in 1986, antibody therapeutics have evolved into a prominent class of therapeutics. These therapeutics have high target specificities and favorable safety profiles. Currently, close to 100 monoclonal antibodies have been approved while more than 500 molecules are being evaluated in clinical trials. Some of the recently approved monoclonal antibody therapies include (in reverse chronological order) Tivdak® (September 2021), Saphnelo® (August 2021), Rybrevant® (May 2021), Ebanga (December 2020) and MARGENZA® (December 2020). The growing popularity of antibody based therapeutics is also reflected from the extensive research being conducted on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments in the past few years.

It is worth highlighting that the process of antibody development, beginning from the discovery to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, antibody discovery and clinical research are capital intensive processes, which, on an average, require investments of around USD 4-10 billion. Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase make it into the clinical phase, and an even lesser number of product candidates enter the market. In order to optimize on internal resource utilization and save costs, pharmaceutical companies are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs). Apart from being considered a viable business strategy, engaging third party service providers offers both time and cost related benefits to the drug / therapy developers. Given the rising demand for antibody based therapeutics and growing preference for outsourcing, we are led to believe that the opportunity for contract service provides and technology developers is likely to increase at a steady rate in the foreseen future.


Scope of the Report



The “Antibody Discovery Services and Platforms Market by Type of Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), Antibody Discovery Method (Library based, Hybridoma based, Single Cell based, Transgenic Animal based), Nature of Antibody Generated (Monoclonal, Bispecific, Antibody-Drug Conjugates, Antibody Fragments) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecast (4th Edition), 2021-2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics. 


In addition to other elements, it includes:


  • An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic). 
  • An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company’s employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed.
  • Elaborate profiles of antibody discovery service providers. Each company profile features a brief overview of the company, its financial information (if available), antibody discovery service portfolios and an informed future outlook. 
  • A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
  • A detailed competitiveness analysis of antibody discovery platforms, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform between 2015 and 2021. 
  • Elaborate profiles of antibody discovery platform providers. Each company profile features a brief overview of the company, its financial information (if available), details on antibody discovery technology / platform(s) offered and an informed future outlook.
  • An assessment of antibody discovery service and platform providers’ capability in different regions, based on a number of relevant parameters. For platform providers, these parameters include number of technologies offered, number of antibody discovery methods employed, and type of antibody discovered. On the other hand, the service providers have been evaluated based on the type(s) of service offered.
  • An analysis of the partnerships that have been established in this domain since 2015, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, and other relevant deals.
  • An analysis of the investments made in this domain, during the period between 2016 and 2021, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery. 
  • Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues. Each profile features a brief overview of the drug, the type of antibody discovery method it employs and the annual historical sales of the product.
  • A case study on antibody humanization and affinity maturation, including a list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends in this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
  • A brief discussion on the imminent opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.
  • An analysis of the deal structure, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.


One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2021-2035. The report also features the likely distribution of the current and forecasted opportunity within antibody discovery services market across [A] the various steps involved in antibody discovery process (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery methods (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). In addition, for estimating the future market opportunities for platform providers, we have considered the likely licensing deal structures and agreements that are expected to be inked in the foreseen future. The future opportunities within the antibody discovery platforms market has been segmented across key geographical regions (North America, Europe and Asia- Pacific). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. 


The report features detailed transcripts of interviews held with the following industry stakeholders:


  • Tracey Mullen (Chief Executive Officer, Abveris Antibody)
  • Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences)
  • Mark Kubik (Chief Business Officer, AvantGen)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
  • Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
  • Sanjiban K Banerjee (Director, AbGenics Life Sciences)
  • Ignacio Pino (Chief Executive Officer and President, CDI Laboratories) 
  • Jeng Her (Chief Executive Officer, AP Biosciences) 
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Christel Iffland (Vice President, Ligand Pharmaceuticals)
  • Aaron Sato (former Chief Scientific Officer, LakePharma)
All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered


  • Who are the leading industry players involved in offering services and technologies related to antibody discovery?
  • What is the relative competitiveness of the players offering services related to antibody discovery, based across different geographies?
  • What tis the relative competitiveness of the technologies pertaining to antibody discovery across different peer groups?
  • Which partnership models are commonly adopted by industry stakeholders offering services and technologies related to antibody discovery? 
  • What is the trend for capital investments in the antibody discovery services and platforms market?
  • How is the current and future market opportunity related to antibody discovery services an platforms, likely to be distributed across key market segments?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Development
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Polyclonal Antibodies
3.6.3. Bispecific Antibodies
3.7. Applications of Antibodies
3.8. Concluding Remarks
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Technology-Based Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques
4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies
5. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Company Size and Type of Service Offered
5.2.6. Analysis by Type of Antibody Discovery Method
5.2.7. Grid Representation: Analysis by Type of Antibody Discovery Method, Type of Antibody Discovered and Location of Headquarters
5.2.8. Analysis by Animal Model Used
5.2.9. Analysis by Type of Antibody Discovered
5.2.10. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
5.2.11. Analysis by Purpose of Antibody Discovery
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1. Antibody Discovery Service Providers based in North America
6.4.2. Antibody Discovery Service Providers based in Europe
6.4.3. Antibody Discovery Service Providers based in Asia-Pacific
7. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers in North America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
7.2.1.2. Antibody Discovery Services Portfolio
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Aragen Bioscience (a GVK BIO company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services Portfolio
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Creative Biolabs
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services Portfolio
7.2.3.3. Recent Developments and Future Outlook
7.2.4. Distributed Bio
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services Portfolio
7.2.4.3. Recent Developments and Future Outlook
7.2.5. ImmunoPrecise Antibodies
7.2.5.1. Company Overview
7.2.5.2. Financial Information
7.2.5.3. Antibody Discovery Services Portfolio
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Integral Molecular
7.2.6.1. Company Overview
7.2.6.2. Antibody Discovery Services Portfolio
7.2.6.3. Recent Developments and Future Outlook
7.2.7. LakePharma
7.2.7.1. Company Overview
7.2.7.2. Antibody Discovery Services Portfolio
7.2.7.3. Recent Developments and Future Outlook
7.2.8. Syd Labs
7.2.8.1. Company Overview
7.2.8.2. Antibody Discovery Services Portfolio
7.3. Antibody Discovery Service Providers in Europe
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services Portfolio
7.3.1.4. Recent Developments and Future Outlook
7.3.2. BIOTEM
7.3.2.1. Company Overview
7.3.2.2. Antibody Discovery Services Portfolio
7.3.2.3. Recent Developments and Future Outlook
7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services Portfolio
7.3.3.3. Recent Developments and Future Outlook
7.4. Antibody Discovery Service Providers in Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services Portfolio
7.4.1.3. Recent Developments and Future Outlook
7.4.2. HD Biosciences
7.4.2.1. Company Overview
7.4.2.2. Antibody Discovery Services Portfolio
7.4.3. Viva Biotech
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Antibody Discovery Services Portfolio
7.4.3.4. Recent Developments and Future Outlook
7.4.4. WuXi Biologics
7.4.4.1. Company Overview
7.4.4.2. Financial Information
7.4.4.3. Antibody Discovery Services Portfolio
7.4.4.4. Recent Developments and Future Outlook
8. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers: List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologies and Platforms
8.3.1. Analysis by Type of Antibody Discovery Method
8.3.2. Analysis by Type of Antibody Discovery Method and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability
9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Library based Antibody Discovery Platforms
9.3.1. Key Assumptions and Parameters
9.3.2. Technology Competitiveness Analysis
9.4. Single Cell based Antibody Discovery Platforms
9.4.1 Key Assumptions and Parameters
9.4.2. Technology Competitiveness Analysis
9.5. Transgenic Animal based Antibody Discovery Platforms
9.5.1. Key Assumptions and Parameters
9.5.2. Technology Competitiveness Analysis
9.6. Hybridoma based Antibody Discovery Platforms
9.6.1. Key Assumptions and Parameters
9.6.2. Technology Competitiveness Analysis
9.7. Other Antibody Discovery Platforms
9.7.1. Key Assumptions and Parameters
9.7.2. Technology Competitiveness Analysis
10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. Harbour BioMed
10.2.1. Company Overview
10.2.2. Antibody Discovery Platforms Portfolio
10.2.2.1. H2L2 Platform
10.2.2.2. HCAb Platform
10.2.3. Recent Developments and Future Outlook
10.3. ImmunoPrecise Antibodies
10.3.1. Company Overview
10.3.2. Financial Information
10.3.3. Antibody Discovery Platforms Portfolio
10.3.3.1. Abthena™
10.3.3.2. B cell Select™
10.3.3.3. DeepDisplay™
10.3.3.4. ModiFuse™
10.3.3.5. ModiPhage™
10.3.3.6. ModiSelect™
10.3.3.7. ModiTune™
10.3.4. Recent Developments and Future Outlook
10.4. Kymab
10.4.1. Company Overview
10.4.2. Antibody Discovery Platforms Portfolio
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3. Recent Developments and Future Outlook
10.5. Ligand Pharmaceuticals
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Antibody Discovery Platforms Portfolio
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4. Recent Developments and Future Outlook
10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Antibody Discovery Platforms Portfolio
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook
11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: Antibody Discovery Service Providers
11.3.1 Regional Capability Analysis: Antibody Discovery Service Providers in North America
11.3.2. Regional Capability Analysis: Antibody Discovery Service Providers in Europe
11.3.3. Regional Capability Analysis: Antibody Discovery Service Providers in Asia-Pacific
11.4. Regional Capability Analysis: Antibody Discovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in North America
11.4.2. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Europe
11.4.3. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers in Asia-Pacific
11.5. Concluding Remarks
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Company (Service / Platform Providers)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type of Partner
12.3.6. Analysis by Type of Partnership and Type of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Most Popular Technologies: Analysis by Number of Partnerships
12.3.9. Regional Analysis
12.3.9.1. Intercontinental and Intracontinental Agreements
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by Amount Invested
13.3.5. Most Active Investors: Analysis by Number of Funding Instances
13.3.6. Regional Analysis by Amount Invested
13.4. Concluding Remarks
14. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market, 2021-2035
14.4. Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2021-2035
14.4.1. Antibody Discovery Services Market for Antigen Designing, 2021-2035
14.4.2. Antibody Discovery Services Market for Hit Generation, 2021-2035
14.4.3. Antibody Discovery Services Market for Lead Selection, 2021-2035
14.4.4. Antibody Discovery Services Market for Lead Optimization, 2021-2035
14.4.5. Antibody Discovery Services Market for Lead Characterization, 2021-2035
14.5. Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2021-2035
14.5.1. Antibody Discovery Services Market for Phage Display, 2021-2035
14.5.2. Antibody Discovery Services Market for Yeast Display, 2021-2035
14.5.3. Antibody Discovery Services Market for Hybridoma Method, 2021-2035
14.5.4. Antibody Discovery Services Market for Transgenic Animal Based Method, 2021-2035
14.5.5. Antibody Discovery Services Market for Single Cell Based Method, 2021-2035
14.5.6. Antibody Discovery Services Market for Other Methods, 2021-2035
14.6. Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2021-2035
14.6.1. Antibody Discovery Services Market for Humanized Antibodies, 2021-2035
14.6.2. Antibody Discovery Services Market for Human Antibodies, 2021-2035
14.6.3. Antibody Discovery Services Market for Chimeric Antibodies, 2021-2035
14.6.4. Antibody Discovery Services Market for Murine Antibodies, 2021-2035
14.7. Global Antibody Discovery Services Market: Distribution by Region, 2021-2035
14.7.1. Antibody Discovery Services Market in North America, 2021-2035
14.7.2. Antibody Discovery Services Market in Europe, 2021-2035
14.7.3. Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2021-2035
14.7.4. Antibody Discovery Services: Market Attractiveness Analysis by Region
15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery Platforms Market, 2021-2035
15.5. Global Antibody Discovery Platforms Market: Distribution by Region, 2021-2035
15.5.1. Antibody Discovery Platforms Market in North America, 2021-2035
15.5.2. Antibody Discovery Platforms Market in Europe, 2021-2035
15.5.3. Antibody Discovery Platforms Market in Asia-Pacific, 2021-2035
16. LICENSING DEAL STRUCTURE
17. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
17.1. Chapter Overview
17.2. Humira® (Adalimumab)
17.2.1. Drug Overview
17.2.2. Discovery Process and Method
17.2.3. Historical Sales
17.3. Keytruda® (Pembrolizumab)
17.3.1. Drug Overview
17.3.2. Discovery Process and Method
17.3.3. Historical Sales
17.4. Stelara® (Ustekinumab)
17.4.1. Drug Overview
17.4.2. Discovery Process and Method
17.4.3. Historical Sales
17.5. Opdivo® (Nivolumab)
17.5.1. Drug Overview
17.5.2. Discovery Process and Method
17.5.3. Historical Sales
17.6. Avastin® (Bevacizumab)
17.6.1. Drug Overview
17.6.2. Discovery Process and Method
17.6.3. Historical Sales
18. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
18.1. Importance of Antibody Humanization and Affinity Maturation
18.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
18.3. Antibody Humanization: Publication Analysis
18.3.1. Publication Analysis: Year-Wise Trend
18.3.2. Publication Analysis: Key Journals
18.3.3. Publication Analysis: Distribution by Animal Model Used
18.3.4. Publication Analysis: Distribution by Antibody Humanization Method
18.4. Antibody Humanization Service and Platform Providers: SWOT Analysis
19. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
19.1. Chapter Overview
19.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
19.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
19.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
19.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
19.6. Future Growth Opportunities in the Asia-Pacific Region
19.7. Expected Increase in Number of Collaborations and Licensing Activity
19.8 Concluding Remarks
20. CONCLUDING REMARKS
20.1. Chapter Overview
21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. Abveris Antibody
21.2.1. Company Snapshot
21.2.2. Tracey Mullen, Chief Executive Officer (Q2 2020)
21.3. Nidus Biosciences
21.3.1. Company Snapshot
21.3.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)
21.4. AvantGen
21.4.1. Company Snapshot
21.4.2. Mark Kubik, Chief Business Officer(Q1 2020)
21.5. Single Cell Technology
21.5.1. Company Snapshot
21.5.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)
21.6. Distributed Bio
21.6.1. Company Snapshot
21.6.2. Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)
21.7. AbCellera
21.7.1. Company Snapshot
21.7.2. Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)
21.8. AbGenics Life Sciences
21.8.1. Company Snapshot
21.8.2. Sanjiban K Banerjee, Director (Q2 2018)
21.9. CDI Laboratories
21.9.1. Company Snapshot
21.9.2. Ignacio Pino, Chief Executive Officer and President (Q2 2017)
21.10. AP Biosciences
21.10.1. Company Snapshot
21.10.2. Jeng Her, Chief Executive Officer (Q2 2017)
21.11. YUMAB
21.11.1. Company Snapshot
21.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
21.12. Antibody Solutions
21.12.1. Company Snapshot
21.12.2. Debra Valsamis, Business Development Associate (Q2 2017)
21.13. Ligand Pharmaceuticals
21.13.1. Company Snapshot
21.13.2. Christel Iffland, Vice President (Q2 2017)
21.14. LakePharma
21.14.1. Company Snapshot
21.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)
22. APPENDIX 1: TABULATED DATA23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 2BScientific
  • 3D Medicines 
  • 3E Bioventures Capital
  • 3SBio
  • A*STAR's Genome Institute of Singapore
  • AAT Bioquest 
  • Ab Initio Biotherapeutics
  • Ab Studio
  • ABBA Therapeutics
  • AbBioSci
  • Abbiotec
  • AbbVie
  • Abcam
  • AbCellera
  • Abcentra
  • Abcepta
  • AbCheck
  • ABclonal 
  • Abcore 
  • ABDYS
  • Abeome
  • Abexxa Biologics 
  • ABGENEX
  • AbGenics Life Sciences
  • Abilita Bio
  • ABL Bio
  • Ablexis
  • Abnova
  • Abpro
  • AbSano
  • Absea  
  • Absolute Antibody
  • Abveris 
  • AbVision
  • Abwiz Bio
  • Abzena
  • Abzyme Therapeutics
  • AC Immune
  • Accel
  • Acceleron Pharma
  • Accurus Biosciences
  • Achaogen
  • ACYTE Biotech
  • Adagene
  • Adaptate Biotherapeutics
  • Adimab
  • Adipogen Life Sciences 
  • Aduro Biotech
  • Advantech
  • Advantech Capital
  • AffinityImmuno
  • Affitech
  • Agency for Science, Technology and Research
  • Agenus
  • Agro-Bio 
  • AIMM Therapeutics
  • Aimmune Therapeutics
  • Aisling Capital
  • Akeagen 
  • Akeso Biopharma
  • Aldevron
  • Alector
  • Alligator Bioscience
  • Allogene Therapeutics
  • Alloy Therapeutics
  • Ally Bridge 
  • AlpaLife 
  • Alta Partners
  • Alvaxa Biosciences (Acquired by Sensei Biotherapeutics)
  • ALX Oncology 
  • alytas therapeutics 
  • Alzheimer's Drug Discovery Foundation
  • Amgen
  • Amgen Ventures
  • Ampersand Capital Partners
  • AMSBIO
  • AnaImmune
  • Analytics Engine
  • AnaptysBio
  • Andera Partners
  • Angel BioScience
  • Antagene
  • Antibody Design Labs
  • Antibody Solutions
  • Antiverse
  • AP Biosciences
  • Apexigen
  • APITBIO 
  • Applied Biological Materials(abm)
  • AprilBio
  • Aptevo Therapeutics
  • Aquila BioMedical
  • Aquila Capital
  • Aquilo Capital Management
  • Aragen Bioscience
  • ARCH Venture Partners
  • Arcus Biosciences
  • argenx
  • Aridis Pharmaceuticals
  • Aro Biotherapeutics
  • Aronora
  • Arsanis
  • ArtiaBio 
  • Artizan Biosciences
  • ARVYS Proteins 
  • Assistant Secretary for Preparedness and Response
  • Astellas Pharma
  • AstraZeneca
  • aTen Therapeutics
  • Atreca
  • ATUM
  • Autolus Therapeutics
  • AvantGen
  • AVIC Capital
  • Aviva Systems Biology 
  • AxioMx
  • Ballast Point Ventures
  • Bayer
  • BBI Group
  • BeiGene
  • Beijing Shijilongxin Investment
  • BenchSci 
  • Berkeley Lights
  • Betta Pharmaceuticals
  • BRL
  • Bharat Innovation Fund
  • Bhat Bio-tech
  • Bill & Melinda Gates Foundation
  • Bio- Rad Laboratories
  • BioAtla
  • BioConnect
  • Biocure Technology 
  • Biocytogen
  • BioDiscovery
  • BioDuro
  • Biogen
  • Biointron
  • BioInvent
  • BiologicsCorp(BIC)
  • Biomatics Capital
  • Biomolecular Discovery Services
  • BioNTech
  • Bio-Rad Laboratories
  • BioSavita
  • Biosion
  • Biotechnology Value Fund
  • Biotecnol
  • BIOTEM
  • Biotheus
  • Bioz 
  • Birchmere Labs
  • Bird Rock Bio
  • Blue Sky BioServices
  • bluebird bio
  • Boehringer Ingelheim
  • Boster Bio
  • Boston Children's Hospital
  • Boxer Capital
  • Brain Canada
  • Bristol-Myers Squibb
  • Broteio Pharma
  • Burrage Capital
  • CALIXAR
  • CANbridge
  • Cancer Prevention and Research Institute of Texas
  • Capra Science 
  • Capralogics 
  • Carterra
  • Catalent Biologics
  • CBC Group
  • CCB Capital
  • CDH Investments
  • CDI Laboratories
  • Celexion
  • Celgene
  • Cell Signaling Technology
  • Cellaria
  • Celsius Therapeutics
  • Centers for Disease Control and Prevention (CDC)
  • Charles River Laboratories
  • ChemBio Discovery Solutions
  • Chemical Abstracts Service (CAS)
  • ChemPartner
  • Chia Tai Tianqing Pharmaceutical 
  • China Life Investment Holding
  • China Life Private Equity Investment
  • ChinaEquity Group (CEG)
  • Chiome Bioscience
  • Chugai Pharmabody Research
  • Chugai Pharmaceutical
  • Cilag
  • Citryll
  • City of Hope
  • Columbia University Irving Medical Center
  • Compass Therapeutics
  • Cormorant Asset Management
  • Corvidia Therapeutics
  • Cosmo Bio
  • Cowen Healthcare Investments
  • Cowin Venture Capital
  • CR-CP Life Science Fund
  • Creative Biolabs
  • Creative Biostructure
  • Creative Diagnostics
  • Crescendo Biologics
  • Crystal Bioscience
  • CSL Behring
  • CStone Pharmaceuticals
  • CureVac
  • CUSABIO
  • Cyclogenix 
  • Cygnus Technologies 
  • DAFNA Capital Management
  • Daiichi Sankyo
  • Dako
  • Dana-Farber Cancer Institute
  • DaTaMabs
  • DBA ITALIA
  • DCVC (Data Collective) 
  • Decheng Capital
  • Defense Advanced Research Projects Agency (DARPA)
  • Delian Capital
  • Denali Therapeutics
  • Detaibio Tech 
  • Diagnostic BioSystems 
  • Dianomi Therapeutics
  • Diatheva
  • Digital Proteomics
  • Distributed Bio
  • DJS Antibodies
  • Dotmatics
  • Dualogics 
  • Early Drug Development Group (E2DG)
  • EcoR1 Capital
  • Efung Capital
  • Eight Roads
  • Eisai
  • Elabscience 
  • Eli Lilly and Company
  • Elpis Biopharmaceuticals
  • Emergent BioSolutions
  • E-nnovation Life Sciences
  • Enterprise Singapore
  • Enthera
  • Entos Pharmaceuticals
  • Envigo
  • EpimAb Biotherapeutics
  • Epiphron Capital Group
  • EUPROTEIN
  • Eureka Therapeutics
  • European Investment Bank
  • European Molecular Biology Laboratory (EMBL)
  • Eurostars
  • Evotec
  • Exelixis
  • Exiris
  • exonbio
  • FairJourney Biologics
  • Faron Pharmaceuticals
  • FCMI Parent
  • Ferring Pharmaceuticals
  • Five Prime Therapeutics
  • Flagship Pioneering
  • Flanders Innovation and Entrepreneurship
  • Floodgate
  • ForteBio
  • Fortune Capital Services
  • Forty Seven
  • F-Prime Capital
  • Fred Hutchinson Cancer Research Center
  • FREJOY Investment Management
  • Fusion Antibodies
  • Fusion Pharmaceuticals
  • G&P Biosciences
  • G.N. Tech Venture
  • Genagon Therapeutics
  • Gene Techno Science
  • GeneBeyond
  • Genedata Biologics
  • GeneFrontier
  • Geneious Biologics
  • General Atlantic
  • GENEWIZ 
  • Genmab
  • Genor Biopharma
  • GenoSafe 
  • Genosco
  • GenScript
  • GenWay Biotech 
  • GHO Capital
  • GIC
  • GigaGen
  • Gilead Sciences
  • GSK
  • Glenmark Pharmaceuticals
  • Glythera
  • Gopher Asset Management
  • GP Healthcare Capital
  • Green Mountain Antibodies 
  • Grenoble Alpes University Hospital
  • Grifols
  • Gustave Roussy
  • GV20 Oncotherapy
  • H3 Biomedicine
  • Harbour BioMed
  • Harpoon Therapeutics
  • HD Biosciences
  • Helix BioPharma
  • Henlix Biotech
  • Heptares Therapeutics
  • Hercules Capital
  • Heritas Capital Management
  • HiFiBiO Therapeutics
  • Hillhouse Capital 
  • HJB
  • Hony Capital
  • HOPU Investments
  • Horizon Discovery 
  • Huaxing Growth Capital
  • Hummingbird Bioscience
  • i2 Pharmaceuticals
  • Ibex Biosciences
  • Icosagen
  • IDG Capital
  • IFB Hamburg
  • IGEM Therapeutics
  • I-Mab Biopharma
  • iMetabolic Biopharma
  • Immatics Biotechnologies
  • Immune Biosolutions
  • Immune Pharmaceuticals
  • ImmunoChina Pharmaceuticals
  • ImmunoGenes
  • Immunome
  • Immunomic Therapeutics
  • ImmunoPrecise Antibodies
  • ImmunoQure
  • In-Cell-Art
  • Incyte
  • Indivumed
  • Inhibrx
  • Innate Pharma
  • Innogene Kalbiotech
  • Innovagen  
  • Innovate UK
  • Innovative Targeting Solutions
  • Innovent Biologics
  • Inotiv 
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Institute for Research in Biomedicine
  • Intarcia Therapeutics
  • Integral Molecular
  • IntelliCyt
  • International Livestock Research Institute (ILRI) 
  • Invenra
  • Invest Northern Ireland
  • Invetx 
  • IONTAS
  • IP  
  • IRBM
  • Isogenica
  • Italian National Institute of Health
  • ITBMed
  • iTeos Therapeutics
  • Janssen Biotech
  • Janssen Pharmaceutical
  • JDRF T1D Fund
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson Innovation
  • Jounce Therapeutics
  • Juno Therapeutics
  • Just Biotherapeutics (Acquired by Evotec)
  • JW Bioscience
  • Kadmon
  • Kairos Therapeutics 
  • Kaken Pharmaceutical
  • Karolinska Institutet
  • Kemp Proteins (formerly known as Kempbio)
  • Keystone Capital Partners
  • Kite Pharma
  • KMD 
  • Kodiak Sciences
  • Kymab
  • LabCorp
  • Labtoo
  • LakePharma
  • LAMPIRE Biological Laboratories
  • Lanier Biotherapeutics
  • Lava Therapeutics
  • Leadgene Biomedical
  • Leading Biology
  • Legend Capital
  • Legend Star
  • Leidos Biomedical Research
  • LEO Pharma
  • LG Chem
  • Life Science Partners
  • LifeArc
  • LifeTein
  • Ligand Pharmaceuticals
  • Light Chain Bioscience
  • Lilly Ventures
  • Lineage Biosciences (Acquired by AbCellera)
  • Linear Venture
  • Lipum
  • Lonza
  • Lundbeck
  • Luye Pharma  
  • LYFE Capital
  • MAB Discovery
  • MabGenesis
  • Mablytics
  • Mabpharm
  • MAbSilico 
  • MabSpace Biosciences
  • Mabtech
  • MabVax Therapeutics
  • MacroGenics
  • Magenta Therapeutics
  • Maine Biotechnology Services
  • Malin
  • Maravai LifeSciences 
  • Massachusetts General Hospital
  • MassBiologics
  • Maverick Therapeutics
  • MD Anderson Cancer Center
  • MedAbome
  • Medicilon
  • MedImmune
  • Medix Biochemica 
  • MEMO Therapeutics
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merus
  • MI-mAbs 
  • Mirae Asset Financial 
  • Mitsubishi Tanabe Pharma
  • Mitsubishi UFJ Capital
  • ModiQuest Research
  • Molcure
  • Molecular Devices
  • Molecular Templates
  • MolMed
  • Moradec
  • MorphoSys
  • Mount Sinai Health System
  • MPM Capital
  • MRL Ventures Fund
  • MSM Protein Technologies
  • Mycenax Biotech
  • Myrio Therapeutics (Myrio)
  • NanoString Technologies
  • Nara Medical University 
  • National Cancer Institute
  • National Center for Research and Development
  • National Centre for Biomolecular Research
  • National Heart, Lung and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institute of General Medical Sciences
  • National Institutes of Health
  • NB Health Laboratory
  • NBE-Therapeutics
  • NeoBiotechnologies
  • NeoClone
  • Neon Therapeutics
  • neoX Biotech
  • Nest.Bio Ventures
  • Neurimmune
  • New World TMT
  • Nidus BioSciences
  • NJCTTQ
  • Nkarta Therapeutics
  • North Coast Biologics
  • NovaRock Biotherapeutics
  • Novartis
  • Novo Nordisk
  • Numab Therapeutics
  • NYU Langone Health
  • Oak Biosciences 
  • Oblique Therapeutics
  • Oceanpine Capital
  • Olympic Protein Technologies
  • Oncothyreon
  • Ono Pharmaceutical
  • Open Monoclonal Technology
  • OrbiMed Advisors
  • OREGA Biotech
  • ORI Healthcare Fund
  • OriGene Technologies
  • OriMAbs
  • OSE Immunotherapeutics 
  • Ossianix
  • Oxford Sciences Innovation
  • Paladin Capital
  • Pandion Therapeutics 
  • Panoply Bio
  • Pascal Biosciences 
  • Pediatric Brain Tumor Consortium
  • Penn Medicine
  • Pennsylvania Industrial Development Authority
  • Perseus Proteomics
  • Pfizer
  • pH Pharma
  • Phanes Therapeutics
  • PharmAbcine
  • PharmaLegacy
  • Pierre Fabre
  • Polaris Partners
  • Potenza Therapeutics
  • PPF 
  • Precision Antibody
  • ProMab Biotechnologies
  • Protein Alternatives (PROALT)
  • ProteoGenix
  • ProtTech
  • Proxima Ventures
  • Purdue Pharma
  • Pure Biologics
  • PX'Therapeutics
  • Qianhai Qinzhi Capital
  • Qiming Venture Partners
  • QIMR Berghofer Medical Research Institute
  • QoolAbs
  • Quan Funds
  • Quebec Consortium for Drug Discovery (CQDM)
  • Queen's University
  • Rapid Novor
  • RayBiotech
  • RD-Biotech
  • Redalpine Venture Partners
  • Redmile 
  • Regeneron Pharmaceuticals
  • Regione Lazio
  • Resonant Therapeutics
  • Retrogenix
  • RevMab Biosciences 
  • Revolve Biotechnologies
  • Rezolute
  • Rhenman & Partners Asset Management
  • Roche
  • Rockland Immunochemicals
  • RubrYc Therapeutics
  • Rx Biosciences
  • SAB Biotherapeutics
  • Sahlgrenska University Hospital
  • Samsara BioCapital
  • Samsara Networks
  • San Diego Biomedical Research Institute
  • Sanofi
  • Sanyou Biopharmaceuticals
  • SARomics Biostructures
  • Sartorius 
  • SBH Sciences 
  • Schroder Adveq
  • Science Exchange 
  • Scotia Biologics
  • Sea Lane Biotechnologies
  • Seeds Capital
  • Selecxine
  • Sensei Biotherapeutics
  • Sequoia Capital China
  • Serum Institute of India
  • Sevion Therapeutics
  • Shandong Boan Biotechnology 
  • Shanghai Junshi Biosciences
  • Shenyang Sunshine Pharmaceuticals
  • Shenzhen GTJA Investment Group
  • Shenzhen Hepalink Pharmaceutical
  • Shenzhen Innovation Capital Investment
  • Shilps Sciences
  • Shire
  • Sichenzia Ross Ference
  • Sichuan Kelun-Biotech Biopharmaceutical
  • Siegfried Holding
  • Silverton Partners
  • Simcere Pharmaceutical
  • Simon Fraser University
  • Single Cell Technology
  • Sino Biological
  • Sinobioway
  • Six.02 Bioservices 
  • SK Holdings
  • Sofinnova Partners
  • Sorrento Therapeutics
  • SOTIO
  • South Dakota Equity Partners
  • SouthernBiotech
  • Specifica
  • Sphere Fluidics
  • Standford University
  • State Development & Investment
  • State of Wisconsin Investment Board (SWIB)
  • Straterx
  • Summit Partners
  • Surface Oncology
  • Surveyor Capital
  • Sutro Biopharma
  • Suzhou Bright Scistar Biotechnology (BSBIO)
  • Suzhou Oriza Holdings
  • Syd Labs
  • Symphogen
  • Synbio Technologies
  • Syngene
  • Synthelis
  • TA Associates
  • Takeda
  • Talem Therapeutics
  • Tanabe Research Laboratories
  • Tasgen Bio-Tech
  • Tasly Biopharmaceuticals
  • TC BioPharm 
  • Technical University of Denmark
  • Telix Pharmaceuticals
  • Temasek Holdings
  • TeneoBio
  • TESARO
  • TetraGenetics
  • Teva Pharmaceutical Industries
  • TG Therapeutics
  • The Antibody Company
  • The University of Texas MD Anderson Cancer Center
  • The University of Tokyo
  • The Wistar Institute
  • Theraclone Sciences
  • Theranyx
  • Thermo Fisher Scientific
  • Thiel Capital
  • Third Point Ventures
  • Third Venture Biopharma
  • ThromboGenics
  • Tizona Therapeutics
  • Tmunity Therapeutics
  • Torch Biosciences
  • TRACON Pharmaceuticals
  • Transcenta Holding
  • Transgene
  • TRIANNI
  • Tri-Institutional Therapeutics Discovery Institute
  • Tsinghua University
  • Twist Biopharma
  • Twist Bioscience
  • UK Innovation & Science Seed Fund
  • University College London
  • University of Navarra
  • University of Oxford
  • University of Southampton
  • University of Surrey
  • University of Technology Sydney
  • University of Texas
  • U-Protein Express
  • US Department of Defense
  • Vaccinex
  • Vall d'Hebron Institute of Oncology
  • Valneva
  • Velabs Therapeutics
  • venBio
  • VERAXA Biotech
  • Vertex Holdings 
  • VI Ventures
  • Vinnova
  • Vir Biotechnology
  • Visterra
  • Vital Venture Capital
  • Viva Biotech
  • Voyager Therapeutics
  • Washington University School of Medicine
  • Watson Investments
  • Wellington Management
  • Wisconsin Alumni Research Foundation
  • Woodford Investment Management
  • Woodford Patient Capital Trust
  • WuXi AppTec
  • Wuxi Biologics
  • XBiotech
  • xCella Biosciences
  • X-Chem
  • Xencor
  • XOMA
  • Y- Biologics 
  • Yale Cancer Center
  • Yinuoke
  • YUMAB
  • Yurogen Biosystems
  • Zai Lab
  • Zebra Biologics
  • Zhejiang Teruisi Pharmaceutical
  • Zheshang Venture Capital
  • ZoonBio Biotechnology 
  • Zumutor Biologics
  • Zurich Cantonal Bank
  • Zydus Cadila
  • Zymeworks

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Monoclonal Antibody Collaboration and Licensing Deals 2019-2024 - Product Image

Monoclonal Antibody Collaboration and Licensing Deals 2019-2024

  • Report
  • 350 Pages
  • Global
From
Antibody Collaboration and Licensing Deals 2019-2024 - Product Image

Antibody Collaboration and Licensing Deals 2019-2024

  • Report
  • 750 Pages
  • Global
From
Antibody Discovery Global Market Report 2024 - Product Image

Antibody Discovery Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Antibody Discovery Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Antibody Type, Nature, Service, End User, and Geography - Product Image

Antibody Discovery Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Antibody Type, Nature, Service, End User, and Geography

  • Report
  • 180 Pages
  • Global
From
Polyclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Polyclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 172 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.